Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2000
11/30/2000WO2000070972A1 New composition
11/30/2000WO2000054745A3 Devices and methods for pain management
11/30/2000WO2000047615A3 Proteins related to neuronal regeneration and uses thereof
11/30/2000WO2000047559A3 5-ht1f agonists
11/30/2000WO2000045832A3 Regulation of anaesthesia
11/30/2000WO2000044900A3 Nucleic-acid binding proteins
11/30/2000WO2000043413A3 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
11/30/2000WO2000042989A3 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
11/30/2000WO2000042172A3 Human homologues of proteins regulated by circadian rhythms
11/30/2000WO2000040241A3 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
11/30/2000WO2000033814A3 Method for administering agents to the central nervous system
11/30/2000WO2000027363A9 Aerosols comprising nanoparticle drugs
11/30/2000WO2000010554A3 Methods and compositions employing optically pure s(+) vigabatrin
11/30/2000DE19924872A1 Antikonvulsiv wirkende Pyrazolo[3,4-d][1,2,3]triazine und Verfahren zu ihrer Herstellung Anticonvulsant acting pyrazolo [3,4-d] [1,2,3] triazines and process for their preparation
11/30/2000DE19924818A1 Substituierte Phenylcyclohexancarbonsäureamide Substituted Phenylcyclohexancarbonsäureamide
11/30/2000DE19923551A1 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht A pharmaceutical preparation containing the active substance diamorphine and its use in a method for the treatment of opiate addiction
11/30/2000CA2716369A1 Phenoxypropylamine compounds
11/30/2000CA2698347A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/30/2000CA2381441A1 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
11/30/2000CA2374926A1 Thiazoloderivatives and pharmaceutical compositions containing them
11/30/2000CA2374915A1 Substituted imidazothiazoles as antidepressant agents
11/30/2000CA2374775A1 1,4-dithiin and 1,4-dithiepin-1,1,4,4, tetroxide derivatives useful as antagonists of the human galanin receptor
11/30/2000CA2374714A1 Purine derivatives, preparation method and pharmaceutical compositions containing same
11/30/2000CA2374674A1 Tumor necrosis factor receptor 5
11/30/2000CA2374668A1 New pharmaceutical combinations for nos inhibitors
11/30/2000CA2374550A1 Antigenic neisserial peptides
11/30/2000CA2374432A1 Dna encoding a human subunit of the 5-ht3 serotonin receptor
11/30/2000CA2374413A1 Human oxidoreductase proteins
11/30/2000CA2374021A1 Methods for regulating protein conformation using molecular chaperones
11/30/2000CA2373967A1 Mag expression promoters
11/30/2000CA2373793A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents
11/30/2000CA2373789A1 Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
11/30/2000CA2373693A1 Seven transmembrane receptor genes
11/30/2000CA2373577A1 .alpha.-amino-.beta.-sulfonyl hydroxamic acid compounds
11/30/2000CA2372887A1 Heterocyclic analgesic compounds and their use
11/30/2000CA2372743A1 New pharmaceutically active compounds
11/30/2000CA2372567A1 Indole-type derivatives as inhibitors of p38 kinase
11/30/2000CA2369746A1 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
11/30/2000CA2363784A1 Method of treatment
11/29/2000EP1055668A1 New 4-arylpiperidine derivatives for the treatment of pruritus
11/29/2000EP1055665A1 3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
11/29/2000EP1054995A1 GABAB-R2a, A 7TM RECEPTOR
11/29/2000EP1054980A1 HUMAN HEPARANASE POLYPEPTIDE AND cDNA
11/29/2000EP1054969A2 Retinoblastoma protein complexes and retinoblastoma interacting proteins
11/29/2000EP1054963A1 Sequences of an ih ionic channel and the use thereof
11/29/2000EP1054904A1 Mucilage, a g-protein-coupled receptor
11/29/2000EP1054898A1 Neuroprotective peptides and uses thereof
11/29/2000EP1054887A1 Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
11/29/2000EP1054885A2 Benzisoxazole derivatives having d4-antagonistic activity
11/29/2000EP1054884A1 Benzofuran-4-carboxamides and their therapeutic use
11/29/2000EP1054881A1 Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
11/29/2000EP1054880A1 TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
11/29/2000EP1054877A1 Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
11/29/2000EP1054876A1 1,3,4-thiadiazoles derivatives as kyn-oh inhibitors
11/29/2000EP1054871A2 Pyrimidines and triazines as integrin antagonists
11/29/2000EP1054869A1 3,4-dihydroquinoline derivatives as nitrogen monoxide synthase (nos) inhibitors
11/29/2000EP1054863A2 2-aminoquinoline derivatives having d4-agonistic activity
11/29/2000EP1054857A1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
11/29/2000EP1054684A1 Method of promoting neuronal cell proliferation and differentiation
11/29/2000EP1054682A2 Use of hyperforin and hyperforin-containing extracts in the treatment and prophylaxis of dementing diseases
11/29/2000EP1054673A1 Benzoxazine compounds for enhancing synaptic response
11/29/2000EP1054672A1 Morphine sulphate microgranules, method for making same and pharmaceutical preparations
11/29/2000EP1054669A2 Use of thiadiazolo[4,3-a]pyridine derivatives
11/29/2000EP1054666A1 Liquid pharmaceutical formulation containing zotepine
11/29/2000EP1054664A1 Method for modulating macrophage activation
11/29/2000EP1054663A1 Topiramate and related derivatives for treating schizophrenia
11/29/2000EP0896539B1 Use of optically pure (+) norcisapride for treating emesis and central nervous system disorders
11/29/2000EP0655055B1 Tachykinin antagonists
11/29/2000CN1275162A Death domain containing receptor 5
11/29/2000CN1275128A Pyrazolo (3,4-D) pyrimidines with anticonvulsive and antialiergic/antiasthmatic action
11/29/2000CN1275127A Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use
11/29/2000CN1274722A Compound capable of inhibiting thrombocyte agglutination and resisting thrombosis and its preparation and application
11/29/2000CN1274718A Novel benzo-[3,4] cyclobutano [1,2-C] pyrroles compound, its prepn. and medicine composition containing the same
11/29/2000CN1058967C Novel pyridine compounds, processes for their preparation and pharmaceutical compositions thereof
11/29/2000CN1058964C Branched-amino-sbustituted thiazoles, process for their preparation and the pharmaceutical compositions which contain them
11/29/2000CN1058884C Effective medicine composition for treatment of rheumatism and its capsule
11/29/2000CA2310174A1 Pyrazolo(3,4-d)(1,2,3)triazines having anticonvulsant activity and processes for their preparation
11/28/2000US6153739 Polynucleotides encoding human uridine diphosphate galactose-4-epimerase
11/28/2000US6153655 Terminally-branched polymeric linkers and polymeric conjugates containing the same
11/28/2000US6153653 Choline compositions and uses thereof
11/28/2000US6153650 Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammation, and gastrointestinal damage.
11/28/2000US6153640 For treating depression, panic attacks, obsessive-compulsive disorders, phobias, impulsive disorders, drug abuse or anxiety
11/28/2000US6153626 For treating pain, gastrointestinal disorders, spinal cord injury
11/28/2000US6153625 For treatment of disorders in which involvement of serotoninergic system has been demonstrated, as in psychiartic disorders such as depression, anxiety, panic attack, schizophrenia, aggression, impulsive disorders
11/28/2000US6153624 Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
11/28/2000US6153620 Opiate receptor antagonist modulates movement disorder
11/28/2000US6153611 As non-dopaminergic antiischemic compounds for treating brain disorders
11/28/2000US6153606 Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
11/28/2000US6153604 Treating disease of nervous system in which pathophysiology of disorder involves excessive excitation of nerve cells by agonists of nmda receptors, comprising administering to guanidine derivative
11/28/2000US6153591 Protecting nervous system following focal ischemia and global ischemia; alzheimer's disease, huntington's disease, prion diseases, parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, alopacia, rheumatoid arthritis
11/28/2000US6153220 Taste-masked formulations
11/28/2000US6153217 Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
11/28/2000US6153189 Human TRK receptors and neurotrophic factor inhibitors
11/28/2000US6153171 Methods for identifying compounds effective for treating neurodegenerative disorders and for monitoring the therapeutic intervention therefor
11/28/2000CA2309505A1 New 4-arylpiperidine derivatives for the treatment of pruritus
11/28/2000CA2309434A1 New 4-arylpiperidine derivatives for the treatment of pruritus
11/28/2000CA2200795C Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
11/28/2000CA2192820C Pyrazolo and pyrrolopyridines
11/28/2000CA2164303C Aromatic acetylcholinesterase inhibitors
11/23/2000WO2000070099A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases
1 ... 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 ... 1833